Device Trial Radar · NCT05806216
Dynamic Quantification of Social-Visual Engagement in Autism Spectrum Disorder (ASD)
Last checked: Nov 20, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
929
Actual
Start
Aug 23, 2023
Primary completion
Mar 27, 2025
Study completion Aug 31, 2025
Sponsor
- Lead sponsor
- EarliTec Diagnostics, IncNot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 10, 2023
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 31 months, up to 84 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to learn about the utility and performance of the EarliPoint System (™): Evaluation for Autism Spectrum Disorder to diagnose and assess autism spectrum disorder (ASD) in children ages 31-96 months (2.5 - 7 years chronological age). The main questions it aims to answer are: 1. To determine the sensitivity and specificity of the EarliPoint device (test) compared to Expert Clinician Diagnosis (ECD) using gold-standard clinical reference assessments in the target age-expanded population. 2. To determine the association between the EarliPoint Verbal Ability Index score and the clinical measures of verbal ability as measured by the Differential Ability Scales (DAS-II). 3. To determine the association between the EarliPoint Nonverbal Ability Index score and the clinical measures of non-verbal abilities as measured by the Differential Ability Scales (DAS-II). 4. To determine the association between the EarliPoint Social Disability Index score and the Autism Diagnostic Observation Schedule, second edition (ADOS-II) Overall Total Score. 5. To determine the association between the EarliPoint Expressive Language Ability Index score and the clinical measures of verbal ability as measured by the Differential Ability Scales (DAS-II). 6. To determine the association between the EarliPoint Receptive Language Ability Index score and the clinical measures of verbal ability as measured by the Differential Ability Scales (DAS-II). 7. To estimate the incidence of adverse device effects associated with the use of the EarliPoint device.
Conditions
- Autism Spectrum Disorder
- Autism
Interventions
EarliPoint DiagnosisDevice
Diagnosis by the EarliPoint System: Evaluation for Autism Spectrum Disorder
Clinically Certain Expert Clinician Diagnosis (CC-ECD)Behavioral
Diagnosis by an expert clinician using gold standard developmental assessment tools.
Primary outcomes
What the sponsor says the trial is designed to measure.
- EarliPoint sensitivityTime frame: at baseline
- EarliPoint specificityTime frame: at baseline
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Southwest Autism Research and Resource Center
Phoenix, Arizona
Emory University - Marcus Autism Center
Altanta, Georgia
University of Iowa
Iowa City, Iowa
6 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.